|

Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation

RECRUITINGSponsored by Xijing Hospital
Actively Recruiting
SponsorXijing Hospital
Started2018-10-30
Est. completion2034-10
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06381271

Summary

The purpose of this multicenter, prospective and observational registry is to evaluate the safety and efficacy of TAVR for treatment of pure severe aortic valve regurgitation. Baseline characteristics, procedural and clinical data will be collected

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* 1\. Patients diagnosed with severe aortic valve regurgitation undergo evaluation by the Heart team and are eligible for TAVR therapy.
* 2\. Patients who understand the purpose of this study, agree to participate in the trial and sign the informed consent form

Exclusion Criteria:

* 1\. Patients who cannot provide informed consent
* 2\. Patients who are treated with TAVR for aortic stenosis
* 3\. Patients who are participating in other clinical trials

Conditions2

Aortic Valve RegurgitationHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.